INS and gestational diabetes: miR-182-3p inhibitor can directly bind to INSR1, a key regulator of the insulin-related pathway, and increase the expression of NSR1 and its downstream signaling pathway in skeletal muscle, thereby promoting GLUT4 translocation as well as glucose uptake and utilization, and thus alleviating the development of GDM [80].